Related Experiment Video

Updated: May 10, 2026

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens
08:47

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens

Published on: April 5, 2019

The evidence for use of pneumococcal conjugate over polysaccharide in children

Ray Borrow1

  • 1Vaccine Evaluation Unit; Public Health England; Manchester Royal Infirmary; Manchester, UK.

Human Vaccines & Immunotherapeutics
|June 5, 2013
PubMed

Insights

Pneumococcal glycoconjugate vaccines are globally used in infants. Pneumococcal polysaccharide vaccines are recommended for children over one year old for wider serotype protection, though their use is under review.

Area of Science:

  • Immunology
  • Vaccinology
  • Pediatrics

Background:

  • Pneumococcal glycoconjugate vaccines are standard in infant immunization globally.
  • Pneumococcal polysaccharide vaccines are recommended for children over one year old.
  • Broader serotype coverage is a key consideration in pneumococcal vaccination strategies.

Purpose of the Study:

  • To review the current use of pneumococcal polysaccharide vaccines in children.
  • To evaluate the efficacy and safety of pneumococcal polysaccharide vaccines in pediatric populations.
  • To compare the benefits of polysaccharide vaccines versus glycoconjugate vaccines for broader serotype coverage.

Main Methods:

  • Literature review of existing studies on pneumococcal vaccines.
  • Analysis of epidemiological data on pneumococcal disease.
  • Comparative assessment of vaccine serotype coverage and immunogenicity.

Main Results:

  • Pneumococcal glycoconjugate vaccines offer protection against common serotypes in infants.
  • Pneumococcal polysaccharide vaccines provide broader serotype coverage, crucial for older children.
  • Ongoing review focuses on the specific benefits and risks for pediatric use.

Conclusions:

  • Pneumococcal vaccination strategies require careful consideration of age and serotype coverage.
  • The role of pneumococcal polysaccharide vaccines in children remains an important area of public health review.
  • Balancing broad protection with vaccine schedules is essential for effective pneumococcal disease prevention.

Keywords:
Pneumococcalconjugatepolysaccharidevaccine

More Related Videos

Experimental Human Pneumococcal Carriage07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes13:53

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

Related Concept Videos

Conjugated Proteins02:50

Conjugated Proteins

Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...